{"id":"ajg555","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By activating guanylate cyclase-C receptors on intestinal epithelial cells, AJG555 increases cyclic GMP levels, which triggers chloride and bicarbonate secretion into the intestinal lumen and enhances intestinal motility. This mechanism promotes stool passage and is designed to treat functional gastrointestinal disorders characterized by constipation or reduced intestinal transit.","oneSentence":"AJG555 is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP to promote fluid secretion and accelerate intestinal transit.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:21.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Irritable bowel syndrome with constipation (IBS-C)"},{"name":"Chronic idiopathic constipation (CIC)"}]},"trialDetails":[{"nctId":"NCT02961556","phase":"PHASE3","title":"General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation","status":"COMPLETED","sponsor":"EA Pharma Co., Ltd.","startDate":"2016-11-15","conditions":"Chronic Constipation","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AJG555","genericName":"AJG555","companyName":"EA Pharma Co., Ltd.","companyId":"ea-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AJG555 is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP to promote fluid secretion and accelerate intestinal transit. Used for Irritable bowel syndrome with constipation (IBS-C), Chronic idiopathic constipation (CIC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}